当前位置: X-MOL 学术Clin. Pharmacokinet. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment
Clinical Pharmacokinetics ( IF 4.6 ) Pub Date : 2023-06-07 , DOI: 10.1007/s40262-023-01256-0
Hengli Zhao 1 , Zhirui Zhao 2 , Kun He 1 , Nianrong Mi 3 , Kai Lou 3 , Xiaolin Dong 3 , Wenyu Zhang 1 , Jingfang Sun 4 , Xinyu Hu 4 , Shuguang Pang 3 , Hong Cheng 2 , Qing Wen 1
Affiliation  

Background

Janagliflozin is a novel sodium–glucose cotransport-2 inhibitor. Despite its remarkable effect in glycemic control, no systematic research has evaluated the effect of renal impairment (RI) on its pharmacokinetics and pharmacodynamics.

Methods

Here, patients with T2DM (n = 30) were divided into normal renal function (eGFR ≥ 90 mL/min/1.73 m2), mild RI (eGFR between 60 and 89 mL/min/1.73 m2), moderate RI-I (eGFR between 45 and 59 mL/min/1.73 m2), and moderate RI-II (eGFR between 30 and 44 mL/min/1.73 m2) groups. They were administered 50 mg janagliflozin orally, and plasma and urine samples were collected for the determination of janagliflozin concentration.

Results

Following oral administration, janagliflozin was rapidly absorbed, with the time to Cmax of 2–6 h for janagliflozin and 3–6 h for its metabolite XZP-5185. Plasma exposure levels were similar for janagliflozin in T2DM patients with or without RI but decreased for the metabolite XZP-5185 in T2DM patients with eGFR between 45 and 89 mL/min/1.73 m2. Janagliflozin significantly promoted the excretion of urinary glucose, even in patients with reduced eGFR. Janagliflozin was well tolerated in patients with T2DM with or without RI, and no serious adverse events (SAEs) occurred during this trial.

Conclusions

The exposure levels of janagliflozin in T2DM patients were slightly increased with worsening of RI (i.e., 11% increase in the AUC in patients with moderate RI compared with the normal renal function group). Despite worsening of renal function, janagliflozin exerted a significant pharmacologic effect and was well tolerated, even in patients with moderate RI, implying a promising role in the treatment of patients with in T2DM.

Registration

China Drug Trial register (http://www.chinadrugtrials.org.cn/I) identifier no.: CTR20192721.

更新日期:2023-06-08
down
wechat
bug